Articles

Read the latest articles relevant to your clinical practice, including exclusive insights from Healthed surveys and polls.

By reading selected clinical articles, you earn CPD in the Educational Activities (EA) category whenever you click the “Claim CPD” button and follow the prompts. 

Dr Linda Calabresi

Hot on the heels of the Choosing Wisely campaign of “do nots” for GPs, the Royal Australasian College of Physicians has released a new list of tests doctors should avoid ordering on pregnant women. The recommendations come from the Society of Obstetric Medicine in Australia and New Zealand (SOMANZ), and include the advice that the D-dimer test should not be used to diagnose venous thromboembolism in pregnant women as it is unreliable. Even though women are five times more likely to develop venous thromboembolism in pregnancy, other investigative tests should be used if a clot is suspected as D-dimer concentrations normally rise in pregnancy regardless of whether thrombosis has occurred, making abnormal results ‘incredibly unreliable’. Another recommendation included in the RACP’s top five low value practices and interventions is to not test for inherited thrombophilia in women who have a history of placenta-mediated complications of pregnancy such as stillbirth, recurrent miscarriages or placental abruption. The rationale behind the recommendation is that while some older, retrospective studies had suggested there might be an association with an inherited clotting disorder and these complications, more recent and more robust evidence has shown there is no link and what’s more, taking low molecular weight heparin is not useful as a preventive measure. The experts also advise not to do repeat tests for proteinuria in women with established  pre-eclampsia. Even though proteinuria is an important diagnostic marker for pre-eclampsia it is has no prognostic value. The level of the proteinuria does not correlate with the severity of the maternal complications, so repeated testing does not help management. MTHFR testing has become popular in certain, mainly allied health circles and is controversial. SOMANZ has made a strong recommendation to not undertake MTHFR polymorphism tests as part of a routine evaluation for thrombophilia in pregnancy. “Patients with the thermolabile variant of the methylenetetrahydrofolate reductase (MTHFR) polymorphism are at higher risk of hyperhomocysteinaemia which has been associated with venous thrombosis. However, these associations appear to hold only in countries lacking grain products nutritionally fortified as a public health measure.” They also say testing may lead to many anxiety-provoking false positives, as up to 15% of the population have homozygous variants, which in most instances appear to have no deleterious effects. The final test on the list is the erythrocyte sedimentation rate. The experts advise do not measure ESR in pregnancy as the levels can vary widely depending on factors such as gestational age and haemoglobin concentrations and therefore the test cannot reliably distinguish between healthy and unhealthy women in pregnancy. The list is the latest publication put out as part of the physician-led Evolve initiative run by the RACP. The aim of the initiative is to help ensure high quality patient care by identifying those practices and interventions that represent poor value to patients in terms of improving their clinical outcome and may even cause harm. According to the media release there are now 17 Evolve lists that have been published across a range of medical specialties, and there are another 15 in development. Ref: https://evolve.edu.au/published-lists/society-of-obstetric-medicine-of-australia-and-new-zealand